People

Physician-scientist and dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania Health System, as identified in BioAdvance’s board directory.

Life science company builder who led BioAdvance as chief executive from 2002 to 2021, with previous biotechnology executive and legal experience.

Physician experienced in pharmaceutical business development, strategic partnerships and venture investing; former Novartis strategic partnerships executive and BioAdvance venture partner.

Drug discovery and development scientist with experience at Trevena, Centocor, GlaxoSmithKline and Merck and an investment committee role at BioAdvance.

Frederick “Rick” Jones is a physician, executive and life science investor experienced in therapeutics and devices, including at Broadview Ventures and Anchor Therapeutics.

Physician and healthcare innovation leader, formerly global head of healthcare for venture capital and startups at Amazon Web Services and chief innovation officer at Virtua Health.

Pulmonologist and clinical development executive experienced in research, regulatory strategy and biopharmaceutical development.

Founding partner of Purposeful Advisors and former global communications leader at NASDAQ, with experience in corporate reputation and strategic communications.

Provides operational and executive administration support, with previous medical device and pharmaceutical business experience.

Manages BioAdvance’s applicant outreach, funding review process and research into regional growth and portfolio development.

Life science finance professional experienced in reporting, budgeting, treasury and internal controls, including at BioRexis and Targeted Genetics.

Physician and engineer experienced in life science investment management, therapeutics strategy and software for drug development.

Physician and biomedical executive experienced in pharmaceutical, biologic and cell therapy development at IVAX, Centocor and Johnson & Johnson.

Life science investor and entrepreneur experienced in medical devices, diagnostics, research tools and digital health; formerly led Kodak’s life science division and Zargis Medical.

Kathy Yi joined Transition Bio's board in 2022. She formerly served as COO of Affini-T Therapeutics and CFO of Cerevel and Sangamo Therapeutics, with earlier finance roles at Novartis and Life Technologies. She holds a chemical engineering degree from UC Berkeley and an MBA from Columbia.

Robert Weeks joined Transition Bio's board in 2024. He advises a private charitable foundation on its endowment and operations and previously served as chief of staff to TD Ameritrade's board chairman. He studied economics and finance at Washington University in St. Louis.

Gregory M. Bokar joined Transition Bio's board in 2026. He is Managing Director of UVB Capital Management, with experience in company formation, licensing, acquisitions and corporate governance. His earlier legal leadership roles included Flagship Pioneering, Sumitomo Pharma America Holdings, Sunovion and Elan.

Diana Bernstein joined Transition Bio's board in 2026 and is a Director at Northpond Ventures focused on biotherapeutics. She previously worked at MRL Ventures Fund and Flagship Pioneering and holds a pharmacology PhD from the University of Pennsylvania. Northpond’s current team lists Diana Bernstein as Director.

Shilpi Arora is President and Chief Scientific Officer of Transition Bio. She previously led discovery and translational biology at Exo Therapeutics. Her experience spans target validation, pharmacology and translational research in oncology, inflammation and rare disease, following cancer biology training at the All India Institute of Medical Sciences.

Sarah Teichmann is a scientific co-founder of Transition Bio. A Cambridge stem cell medicine professor and former head of cellular genetics at the Wellcome Sanger Institute, she co-founded and co-leads the Human Cell Atlas initiative.

Peter St George-Hyslop is a scientific co-founder of Transition Bio and a Columbia University neurology professor. His research identifies genetic and molecular causes of neurodegeneration, including Alzheimer's disease.

Biologics and respiratory drug discovery scientist, chief scientific officer of Spirovant and former respiratory, inflammation and autoimmune research leader at MedImmune/AstraZeneca.

Physician and clinical development executive experienced in diabetes, stem cell therapies and medical devices, formerly chief medical officer at ViaCyte and named chief medical officer of Aardvark Therapeutics in Tolerance Bio’s published biography.

Dana-Farber immunology and cellular therapy researcher studying immune recovery after stem cell transplantation and cancer immunotherapy; formerly executive director of its Cell Manipulation Core Facility through June 2024.

University of Miami cellular transplantation scientist, inventor of pancreatic islet isolation technology and director emeritus of the Diabetes Research Institute.

Columbia University immunologist researching transplantation, tolerance induction, xenotransplantation and type 1 diabetes.

Cell therapy bioanalytical scientist experienced in stem-cell-derived NK cell assays and GMP quality control at HebeCell, with doctoral research into microglia and neurodegeneration.

Immunologist experienced in research, medical affairs and scientific communications at JDRF, Provention Bio, Sanofi and Orna Therapeutics.

Biotechnology regulatory affairs and research executive with previous leadership roles at Sanofi and Provention Bio, including development of type 1 diabetes immunotherapies.

Biologics and cell and gene therapy programme manager experienced in CMC strategy and cross-functional development at Beam Therapeutics and Regeneron.

Preclinical and clinical immunology and pharmacology leader experienced in biomarkers and therapeutic development at Roche, Janssen and Provention Bio/Sanofi.

Cell and gene therapy manufacturing scientist with experience at Beam Therapeutics and Semma Therapeutics and a background in mechanobiology and nanomaterials.

Biopharmaceutical business development and alliance management executive previously at Provention Bio, Allergan, Actavis, Watson Pharmaceuticals and Eden Biodesign.

Certified public accountant experienced in financing, accounting and financial operations for biotechnology companies including Provention Bio and Iveric Bio.

Stem-cell scientist at the University of Florida researching functional human thymic tissue and pancreatic islets derived from pluripotent stem cells.

Thomas Hughes, listed as Tom Hughes by Ride Therapeutics, serves on its board. He previously led Deutsche Asset Management and held senior trading and financing roles at Merrill Lynch. He co-founded Fieldpoint Private Bank & Trust and studied naval architecture and marine engineering at the United States Merchant Marine Academy.

Al Kelly is a board member of Ride Therapeutics and an advisory director at Berkshire Partners. He formerly led Visa as CEO and chairman and held executive roles at American Express. He earned undergraduate and MBA degrees at Iona University.

David Weitz is a scientific co-founder of Ride Therapeutics. A Harvard professor and Wyss Institute faculty member, he studies soft matter, biophysics and biomaterials and has helped establish multiple technology companies. He is also a scientific co-founder of Transition Bio.

Tuomas Knowles is a scientific co-founder and board member of Ride Therapeutics. A Cambridge physical chemistry professor, he researches protein aggregation, self-assembly and microfluidic methods. His other spinouts include Transition Bio, WaveBreak Therapeutics and Xampla. He is also CTO, scientific co-founder and executive director of Transition Bio.

George Kelly Martin, also known as G. Kelly Martin, is chairman and co-founder of Ride Therapeutics. He also co-founded Transition Bio. His previous leadership roles include CEO of Elan, Malin, Novan and Radius Health and senior positions at Merrill Lynch. He studied politics at Princeton. He is also executive chairman and co-founder of Transition Bio.

Emer Reynolds leads alliances and corporate strategy at Ride Therapeutics. She previously held senior roles at Elan, Malin, Wren Therapeutics and Radius Health, working across partnerships, business development, investor relations and corporate affairs. She is a University College Dublin graduate.

Timothy Welsh leads platform technology at Ride Therapeutics, which he co-founded. He previously helped build technology platforms at Transition Bio and Flagship Pioneering and earned a doctorate in biophysical chemistry at Cambridge.

Samuel Cohen is CEO and co-founder of Ride Therapeutics and serves on its board. He previously co-founded and led Wren Therapeutics and helped found Transition Bio. His background includes biotechnology investing at Malin, strategy consulting at BCG and biophysical chemistry research at Cambridge. He is also an executive director and co-founder of Transition Bio.

John S. Weinberg serves as executive vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Jennifer L. Taylor serves as nonvoting cf adult care center representative at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eric J. Sorscher serves as nonvoting medical advisory council chair at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Dodzie Sogah serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Steven Shak serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eric C. Schneider serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eric R. Olson serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Kate O'Donnell serves as national volunteer leadership council chair at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Robert H. Niehaus serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

David A. Mount serves as treasurer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Paul A. Motenko serves as nonvoting advisor at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Peter J. Mogayzel Jr. serves as nonvoting pediatric cf care center representative at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Catherine C. McLoud serves as nonvoting chair emeritus at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Carole B. Griego serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

D. Paul Flessner serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Teresa L. Elder serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Elise Eberwein serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Louis A. DeFalco serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Dominic J. Caruso serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

James (Jamie) R. Butler, II serves as nonvoting advisor at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Jessica H. Boyd serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

KC Bryan White chairs the Cystic Fibrosis Foundation’s board of trustees. She joined the board in 2005 and became chair in 2022. A founding member and former chair of the Foundation’s Adult Advisory Council, she helped establish BreatheCon and created the ROSE UP fundraising event.

Timothy A. Waire, Jr. serves as senior vice president and chief information officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Sue Sullivan serves as vice president of community partnerships at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Adela Skenderasi serves as chief investment officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eleana Seek serves as senior vice president and chief audit and risk officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Steven Rowe serves as executive vice president and chief scientific officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Molly Riley serves as senior vice president of field management at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Yvonne Massenburg serves as senior vice president and chief people officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Marin Goings serves as senior vice president and chief of strategy at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Albert Faro serves as senior vice president and chief medical officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Mary B. Dwight serves as senior vice president and chief policy and advocacy officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Heather Culp is senior vice president and chief development officer of the Cystic Fibrosis Foundation, joining on August 10, 2026 to lead fundraising and donor engagement. Previously she led philanthropy at University of Maryland Medicine and fundraising for Johns Hopkins neurology and brain sciences. She trained in English at Washington College and law at the University of Maryland and practiced law before moving into philanthropy.

JP Clancy serves as senior vice president of clinical research at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Michael Cavadel serves as senior vice president and chief legal officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Kathryn Brown serves as senior vice president and chief communications and marketing officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Irena Barisic serves as executive vice president and chief operating and financial officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Michael P. Boyle is president and chief executive officer of the Cystic Fibrosis Foundation and a member of its board of trustees. A physician and cystic fibrosis clinical researcher, he previously led the Foundation’s therapeutics development from 2015 to 2019. He trained at Johns Hopkins, founded its Adult CF Program and remains an adjunct professor who sees patients there.

Consulting partner at Axon, promoted after more than twelve years with the firm. The firm’s own announcement identifies his full name as Carlos Gómez Herrero.

Axon group managing partner and a director of its regulated Spanish fund management subsidiary. Official CNMV records verify the full legal name and management-company board role.

Axon group managing partner and a director of its regulated Spanish fund management subsidiary. Official CNMV records verify the full legal name and management-company board role.

Nathan Higginson-Scott was appointed chief research and development officer of Gensaic in January 2026 to lead scientific strategy and therapeutic development. He previously served as chief technology officer and senior vice president of drug creation at Seismic Therapeutic and as vice president of biotherapeutics at Pandion Therapeutics. Earlier, he worked at Pfizer. He earned a doctorate in molecular immunology and a master’s degree from Imperial College London and a microbiology degree from the University of Kent.

Karina Thorn is a board observer at Gensaic and a Novo Nordisk nucleic acid research leader. She has a PhD in biochemistry from the University of Copenhagen and joined Novo Nordisk in 2014, following several years working in Boston.

Jill Milne joined Gensaic’s board in June 2026. She co-founded Catabasis Pharmaceuticals and previously served as its CEO and as president and CEO of Astria Therapeutics. She brings scientific, operational and public-company leadership experience to Gensaic’s cardiometabolic and RNAi programs.

Neil Exter joined Gensaic’s board in May 2026. A retired partner of Third Rock Ventures, which he joined in 2007, he has more than 30 years of biotechnology and technology operating, business development and strategy experience. He earned engineering degrees from Cornell and Stanford and an MBA from Harvard.

Liang Schweizer joined Gensaic’s board in May 2026. She is founder and CEO of DISruptive Oncology and previously served as chair and CEO of HiFiBiO Therapeutics. Gensaic identifies her experience in scientific leadership and global biotechnology company building.

Sungmin Baek is senior scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Gabrielle Mitchell-Lee is senior research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Neo Ruiz is research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Emanuel Burgos is computational biologist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Evans Wralstad is senior scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Jonathan Sands is senior research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Maya Orzach is senior research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Maggie Lejeune is associate scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Alex Wang is senior scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Jonathan Hsu is chief technology officer and co-founder of Gensaic. An MIT PhD alumnus from 2022, he founded the company with Lavi Erisson and Uyanga Tsedev in 2021. Gensaic combines protein engineering and machine learning to develop tissue-selective delivery systems.

Uyanga Tsedev is chief scientific officer and co-founder of Gensaic. She earned her MIT master’s degree in 2015 and doctorate in 2021, researching engineered phages in Angela Belcher’s laboratory. She is principal investigator on Gensaic’s NIH-supported phage-derived gene delivery project for muscle diseases.

Lavi Erisson is CEO, co-founder and a board member of Gensaic. A physician and MIT Sloan MBA alumnus, he previously worked in drug development at Teva and as chief medical and business officer of Iterative Health. He founded Gensaic with Uyanga Tsedev and Jonathan Hsu in 2021.

Engineer, programmer and co-founder of Eholo’s psychology practice management platform.

Health psychologist and co-founder of Eholo, developing tools to simplify the daily administration of psychology practices.

Distinguished researcher at Universitat Jaume I experienced in biomedical research management and technology transfer.

CSIC senior researcher at the Severo Ochoa Center for Molecular Biology studying the molecular mechanisms of neurological disorders.

Biotechnology strategy and business development adviser with previous leadership roles at Digna Biotech and OWL Metabolomics and pharmaceutical experience at Boehringer Ingelheim.

Pharmacologist and biotechnology executive experienced in endocrine therapies and steroid sulfatase inhibitors, including roles at Oxandia, Gliagenesis and Estryx Pharma.

Neurologist and clinical group coordinator at Fundación CIEN, experienced in dementia research and clinical trial design.

Neurologist specialising in Alzheimer’s disease and co-founder and medical director of Fundación ACE.

Universidad Pablo de Olavide professor researching cognition, nociception, aging and steroid sulfatase inhibitors in neurodegenerative disease.

Aging biology researcher studying steroid sulfatase inhibition and neurodegeneration in animal models; co-inventor of patents underpinning ONESTX.

Neuroscience and pharmacology researcher with previous senior preclinical development roles at WeLab Barcelona and ESTEVE.

Molecular biologist and research project manager experienced in biotechnology development and technology transfer into clinical development.

Neuroscientist experienced in preclinical and clinical development, biomarkers and neuroimaging, with previous roles at Noscira, Syneos Health and Peaches Biotech.

Genetics and longevity researcher and professor at Universidad Pablo de Olavide, developing the steroid-sulfatase research underpinning ONESTX.

Pharmacist and biotechnology entrepreneur experienced in diagnostics, research management and technology transfer; also a founder and chief executive of Biomedal.

External investment adviser to the Mar Océana board associated with Eoniq Mediterranean Seed Fund II, contributing expertise in artificial intelligence engineering and research strategy.

Supports Eoniq portfolio companies with commercial development, customer acquisition and scaling, and manages deal flow.

Eoniq investment professional, former nanophysicist and CFA charterholder, with experience evaluating private companies and investment portfolios in southern Europe.

Eoniq general partner experienced in public and private investment programmes and entrepreneurial ecosystems in Spain, particularly Andalucía.

Entrepreneur and venture investor leading Eoniq Fund. The official incorporation notice for Fund II identifies him as Thomas Caspar Nigel Horsey and as the individual representative of its corporate administrator Mar Océana.

Adviser to Ovid Therapeutics following his transition from chief financial officer in July 2026, when Charles Carter succeeded him. Ovid’s announcement states he will remain an adviser through the end of 2027; he is not its current CFO.

Neuroscientist and co-founder of Ovid Therapeutics, established with Jeremy Levin in April 2014. Previously served as Ovid’s president and chief scientific officer; its 2019 proxy describes his planned retirement from the board. This is a historical founding affiliation, not a current executive appointment.

Scientific and clinical adviser to Ovid Therapeutics and neurosurgeon at the University of Chicago Medicine, where he directs neurovascular surgery and researches cerebral cavernous malformations. Ovid’s directory misspells his first name as Isam and incorrectly places Imad Najm’s biography beneath it; his identity and research are corroborated by University of Chicago sources.

Scientific and clinical adviser to Ovid Therapeutics and neurogenetics researcher at Baylor College of Medicine. Directs the Blue Bird Circle Developmental Neurogenetics Laboratory and studies genetic regulation of neuronal excitability, including epilepsy associated with Alzheimer’s disease and glioblastoma.

Scientific and clinical adviser to Ovid Therapeutics and neuroscience professor at Tufts University School of Medicine. Her research examines epilepsy, mood disorders, GABAergic inhibition and neurosteroids. Holds a neuroscience PhD from George Washington University.

Scientific and clinical adviser to Ovid Therapeutics and emeritus chief of pediatric neurology at UCLA Health. A clinician and researcher focused on epilepsy and child neurology, with an MD from Tulane and a PhD in medicinal chemistry from Washington.

Scientific and clinical adviser to Ovid Therapeutics. An epilepsy specialist at Cleveland Clinic, where he directs the Epilepsy Center and studies epileptogenesis, focal cortical dysplasia and epilepsy surgery. Ovid’s site places his detailed biography beneath the separate Issam Awad heading; that misplaced biography is not attributed to Awad.

Director of Ovid Therapeutics. A biotechnology founder and former investment banker who co-founded Exelixis, Epikast, Anadys Pharmaceuticals and Cellzome. His prior roles include chairing Biogen and investment banking leadership at Cowen and PaineWebber.

Director of Ovid Therapeutics and RNA interference drug discovery scientist associated with Alnylam Pharmaceuticals. Joined Alnylam in 2005 after Bristol Myers Squibb and contributed to development of siRNA delivery approaches. Distinct from Kevin FitzGerald, the Epsilogen executive already recorded in Adex.

Lead independent director of Ovid Therapeutics and chair of its Nominating and Corporate Governance Committee. A corporate governance lawyer with a long career at Cahill Gordon & Reindel and earlier service at the SEC. Holds a JD from Harvard Law School.

Director of Ovid Therapeutics and chair of its Audit Committee. Previously served as chief financial officer and treasurer at Intercept Pharmaceuticals and as chief executive officer and CFO at DOV Pharmaceutical. Holds an MBA from Wharton.

Director of Ovid Therapeutics and chair of its Science and Technology Committee. A physician-scientist and biotechnology entrepreneur with faculty roles at Harvard and the Broad Institute. Founded biotechnology companies and leads research that includes applying machine learning to therapeutic target discovery; this personal research does not establish an Ovid AI drug platform.

Senior vice president of clinical development at Ovid Therapeutics, responsible for clinical strategy and medical affairs. Joined in 2020 after clinical development leadership at Marinus Pharmaceuticals, with experience in rare and general epilepsies. Holds a doctorate in physiology and biophysics from NYU and a psychology degree from Cornell.

Chief scientific officer of Ovid Therapeutics, responsible for non-clinical science, research and academic collaborations. Previously held R&D leadership at Generation Bio, Wave Life Sciences, Vertex and GSK’s neuroscience group. Holds a doctorate from Rockefeller University.

Chief business officer of Ovid Therapeutics, joining in July 2026. His prior roles include business development leadership at Soleno Therapeutics, chief operating officer of Codexis, and business and commercial leadership at Sierra Oncology. Holds an MBA from UC Berkeley and an MS in biochemistry and molecular biology from UCLA.

Chief medical officer of Ovid Therapeutics. Previously served as chief medical officer of Vigil Neuroscience and Affinia Therapeutics, and held clinical development leadership at Novartis Gene Therapies and AveXis. Earlier led the NIH Office of Rare Diseases Research. A neurologist with an MD from Bonn and an MS in biostatistics from Columbia.

Chief strategy officer of Ovid Therapeutics, known as Tori Fort. Joined in 2025 and leads enterprise strategy, investor relations and strategic initiatives. Previously led strategy and corporate affairs at Frontier Medicines and founded the biotechnology consultancy uncapped within WPP.

Chief financial officer of Ovid Therapeutics, promoted in July 2026 after joining in 2024 to lead finance and financial planning. Previously held CFO positions at CERo Therapeutics, iCAD and GI Dynamics, with earlier roles at Transkaryotic Therapies and Mercer Management Consulting.

President and chief executive officer of Ovid Therapeutics, appointed CEO effective January 1, 2026 after serving as president and chief operating officer. Joined Ovid in 2021 and led its operations and strategic transformation. Previously built a reputation and risk management business at Syneos Health.

Leads investment solutions, advisory services and discretionary portfolio management at Creand Asset Management in Spain. Joined the firm in 2015 and began leading its Spanish fund advisory and management team in 2023.

Investment director at Creand Asset Management in Spain since 2023, leading analysis and management of equities, fixed income, alternative investments and ESG. Joined Creand in 2015, after working at Deloitte and FCS Asset Management.

Also published as Luis Buceta Casteleiro. Managing director of business and investments at Creand Asset Management in Spain, registered as a general manager of Gesalcalá. Joined the Creand group in 2016 and previously worked at Chase Manhattan Bank and BNP Paribas.

Director of Graviton Bioscience, founder and chief executive officer of Optima Asset Management, and vice-chairman of FFT Wealth Management. Launched Optima’s flagship fund in 1988; earlier career included Kidder Peabody and UBS PaineWebber.

Director of Graviton Bioscience and chemistry professor at Princeton University. Shared the 2021 Nobel Prize in Chemistry with Benjamin List and has advised pharmaceutical companies and founded biotechnology companies.

Chairman of Graviton Bioscience and managing partner and co-founder of Pontifax, a life science investment firm. His biotechnology board experience includes Keros Therapeutics, Kamari Pharma, Luris Therapeutics and Adcytherix, with earlier directorships at Kite Pharma and Prevail Therapeutics.

Senior vice president of clinical and scientific strategy at Graviton Bioscience. An oncology physician and researcher with experience leading clinical trials and translational research; his published work includes AI-assisted drug repurposing research during COVID-19. This personal research history does not establish an AI platform at Graviton.

Senior vice president and head of chemistry at Graviton Bioscience. Previously led chemistry research at Kadmon and helped establish its ROCK2 program; earlier research included Alzheimer’s disease at Wyeth and metabolic disorders at Merck. Holds a PhD in organic chemistry from the University of Illinois Urbana-Champaign.

Senior vice president of translational medicine at Graviton Bioscience. Previously held translational medicine leadership at Equilibre and led immunology at Kadmon, where she contributed to development of belumosudil for chronic graft-versus-host disease. Holds a PhD in immunology from the Weizmann Institute.

Senior vice president, general counsel and head of compliance at Graviton Bioscience. His legal experience covers healthcare commercial transactions, regulation, intellectual property and risk management. Holds degrees from Harvard, Yale and NYU School of Law.

Senior vice president of business development and chief of staff at Graviton Bioscience. With the company since its inception, she oversees collaborations, financing and internal business operations. Previously worked in strategy at life science companies and investment management at Goldman Sachs.

Executive vice president responsible for research, preclinical development and CMC at Graviton Bioscience. Involved since the company’s inception; previously led preclinical research and CMC at Equilibre and small molecule retomer drug discovery at MeiraGTx. Holds a PhD in biochemistry with a neuroscience research background.

Chief medical officer and senior vice president at Graviton Bioscience. Previously led clinical research at Equilibre Biopharmaceuticals and held radiology faculty positions at Mount Sinai and NYU, with research in breast MRI and PET/MRI. Holds an MD from UCLA.

Founder and chief executive officer of Graviton Bioscience, a developer of ROCK2 inhibitors for neurological, immune and fibrotic disorders. Previously founded and led ImClone Systems and Kadmon, and founded MeiraGTx; his background includes academic biomedical research.

Blue Opal Capital partner with over twenty years of investment management experience. Previously helped build Abu Dhabi Investment Authority’s venture capital programme, focusing on venture capital fund investments and co-investments.

Partner responsible for Blue Opal Capital’s venture investment activities. Previously co-founded PKRS.AI and worked on venture capital fund investments and co-investments in the private equity department of Abu Dhabi Investment Authority.

Co-founder of Blue Opal Capital and its chief compliance officer. Previously a managing director at BRG in New York and head of private equity valuation activities at Abu Dhabi Investment Authority.

Dan Estes serves as Director at Sudo Biosciences. Sudo co-founder and board director and Frazier Life Sciences general partner. Invests in and forms private biopharmaceutical companies; previously consulted with McKinsey and trained in biomedical engineering.

Dave Johnson serves as Director at Sudo Biosciences. Sudo board director and founder and CEO of Solve Therapeutics. Previously led VelosBio and Acerta Pharma and chaired Lengo Therapeutics.

Chris Gagliardi serves as Director at Sudo Biosciences. Sanofi Ventures biotechnology investor and Sudo director. Previously worked in life sciences strategy consulting at L.E.K.; trained in chemistry.

Shinichiro Fuse serves as Director at Sudo Biosciences. Biotechnology investor at TPG Life Sciences Innovation with earlier investment and company-building experience at MPM Capital and business development at bluebird bio.

Terrie Walker-Smith works in clinical trial management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Gerry Thomas works in head of r&d project management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Fenella Smith works in executive assistant at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Zainib Shabir works in clinical trial management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Kejal Patel serves as Vice President, Clinical Operations at Sudo Biosciences. Clinical operations leader with earlier roles at Stargazer Pharmaceuticals, Outpost Medicine and Takeda, including global Phase 2b and Phase 3 trials.

Waylon Parham serves as Vice President, Finance & Controller at Sudo Biosciences. Finance executive and certified public accountant with previous controller and accounting leadership at Glympse Bio, Altavant Sciences and Syneos Health.

Peadar O’Donohoe serves as Vice President, Clinical Development at Sudo Biosciences. Clinical development physician with experience across neurology, sleep disorders, oncology and hematology; previously practiced anesthesiology and critical care.

Matt Nelan works in finance at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Kelly Munro works in clinical pharmacology at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Cliona MacSweeney works in head of translational medicine at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Sarah Loughrey-Jennings works in clinical trial management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Jack Kempster works in accountant at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Anitha Jeyanthan works in r&d project management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Roy Gray serves as Vice President, Non-Clinical Development at Sudo Biosciences. Nonclinical development leader who previously worked at Kadence Bio and GW Pharmaceuticals, including epilepsy drug development.

Sally Fillingham works in clinical trial administration at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Mark Evans works in neuropharmacology at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Rachel Eccles serves as Vice President, Translational Pharmacology at Sudo Biosciences. Translational pharmacology scientist with previous project leadership at BenevolentAI and Pfizer and experience consulting on preclinical and IND-enabling development.

Vassilios Aslanis serves as Vice President, Clinical Pharmacology at Sudo Biosciences. Clinical pharmacology and pharmacometrics specialist with earlier leadership roles at Galecto, Ipsen, Novartis and Pierre Fabre.

Marsilio Adriani works in director, translational biology at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Anjali Pandey serves as Senior Vice President, Medicinal Chemistry at Sudo Biosciences. Has led Sudo’s medicinal chemistry work since its 2020 founding. Previously worked at Lengo Therapeutics and in oncology companies affiliated with BridgeBio.

David Hennings serves as Senior Vice President, Chemistry, Manufacturing and Controls at Sudo Biosciences. Chemistry, manufacturing and controls specialist who previously worked on neurodegenerative drug development at Cortexyme and spent fourteen years at Array Biopharma.

Paul Bavier serves as Chief Legal Officer at Sudo Biosciences. Biotechnology lawyer with previous leadership roles at HilleVax, VelosBio, Avedro and Biodel. Holds a University of Michigan law degree.

Imran Babar serves as Chief Business & Financial Officer at Sudo Biosciences. Business and finance executive with prior roles at the orphan drug accelerator Cydan II and OrbiMed; co-founded Arvada Therapeutics and serves on the Rare Genomics Institute board.

Gordon McMurray serves as Chief Development Officer at Sudo Biosciences. Drug development scientist who co-founded Outpost Medicine and previously led research across neuroscience, pain and urology at Pfizer; earlier worked in pharmacology at Oxford.

Ian Mills serves as Chief Medical Officer at Sudo Biosciences. Physician and clinical development leader with previous roles at Outpost Medicine, Mitsubishi Tanabe and Pfizer; also an entrepreneur-in-residence with Frazier Life Sciences.

Scott Byrd serves as Chief Executive Officer at Sudo Biosciences. Biopharmaceutical executive and Frazier Life Sciences entrepreneur-in-residence. Previously led Outpost Medicine, chaired Acacia Pharma, and oversaw commercialization at Cadence Pharmaceuticals.

Senior Advisor to Enavate Sciences and biotechnology entrepreneur. Led Delphi Ventures’ biotechnology practice from 2001 through 2023; previously worked in healthcare finance at J.P. Morgan and conducted immunology research at Genentech.

Senior Advisor to Enavate Sciences and founder and managing director of Beacon Prince Partners. Previously led immunology and oncology strategy at Sanofi, ran NKT Therapeutics and Alinea Pharmaceuticals, and invested with Boston Millennia Partners. Trained in medical oncology.

Enavate Sciences board member and physician with healthcare investment experience at Patient Square Capital and HealthQuest Capital. Previously trained in internal medicine at Stanford and holds Stanford medical and business degrees. Trit Garg is a healthcare investment principal at Patient Square Capital and an Enavate Sciences director. He previously invested at HealthQuest Capital and trained in internal medicine at Stanford. He holds Stanford medical and business degrees.

Enavate Sciences board member and Patient Square Capital partner who leads Patient Square Insights. Previously held leadership roles at BCG, QIAGEN and McKinsey, including genomic clinical decision support and healthcare analytics. Holds a UCLA doctorate in cognitive neuroscience. Laura Furmanski is a partner and leads Patient Square Insights. She previously led healthcare consulting and analytics work at Boston Consulting Group and QIAGEN’s bioinformatics business, including genomic clinical decision software.

Enavate Sciences board member and founding partner of Patient Square Capital. A physician and healthcare investor with prior roles at KKR and Linden Capital Partners; trained at Harvard and MIT and studied neuroscience at Oxford. Neel Varshney serves as Founding Partner at Patient Square Capital. Earlier experience includes a Managing Director on KKR’s Americas Health Care Team.

Chairman of Enavate Sciences and Managing Partner of Patient Square Capital. Previously led KKR’s Americas healthcare investment team and helped establish its healthcare industry group; studied at Stanford. Jim Momtazee is Patient Square Capital’s managing partner and a healthcare investment executive. He previously helped establish KKR’s healthcare investment group and led its Americas healthcare team. He also chairs Enavate Sciences.

Vice President at Enavate Sciences focused on sourcing, diligence and investment execution. Previously led portfolio strategy and business development at Code Biotherapeutics and invested in biopharma at NEA; began his career in healthcare banking at Credit Suisse.

Vice President on Enavate Sciences’ investment team. Evaluates opportunities and supports portfolio development, drawing on prior work at Roivant and rare disease gene therapy development at Aruvant.

Business Manager at Enavate Sciences, overseeing operational processes and strategic initiatives. Previously worked in group operations at Credit Suisse and built retail and hospitality operations; studied sociology in India.

Principal at Enavate Sciences, executing investments and supporting portfolio operations. Previously invested with Longitude Capital and worked in healthcare investment banking at J.P. Morgan. Studied neuroscience at Penn and finance at Wharton.

Executive Vice President for Search and Evaluation at Enavate Sciences. A physician and investment professional with experience at OrbiMed and in healthcare investment banking at Credit Suisse and Merrill Lynch; supports investment selection and portfolio governance.

Executive Vice President for Commercialization at Enavate Sciences. Helps evaluate investments and supports portfolio strategy, partnerships and commercialization. A trained physician, he previously spent more than two decades with McKinsey’s life sciences practice. He also serves as a director of Sudo Biosciences.

Chief Executive Officer of Enavate Sciences and a member of its board. Previously led investment banking at SVB Leerink and worked in healthcare investment banking at Merrill Lynch, advising life science companies on financing and acquisitions. He also serves on the board of Graviton Bioscience. James Boylan serves as Senior Advisor at Patient Square Capital.

Jeff Chen is an Asahi Kasei corporate venture capital managing director who joined the team in 2023 after leading product management and development at semiconductor company Crystal IS. He holds a Stony Brook electrical-engineering doctorate and an NYU Stern MBA.

Leonard Zon serves as Scientific Advisor at CAMP4 Therapeutics. CAMP4 scientific co-founder and physician-scientist affiliated with Boston Children’s Hospital and Harvard; advises the company on genetic disease biology.

Christopher Walsh serves as Scientific Advisor at CAMP4 Therapeutics. Physician-scientist studying the genetics of brain development and neurological disease.

Benjamin Neale serves as Scientific Advisor at CAMP4 Therapeutics. Genetics researcher at the Broad Institute and co-director of its Stanley Center for Psychiatric Research.

Rachel Meyers serves as Scientific Fellow at CAMP4 Therapeutics. RNA therapeutics scientist serving as a scientific fellow at CAMP4.

Wendy Chung serves as Scientific Advisor at CAMP4 Therapeutics. Physician-scientist and human genetics specialist advising CAMP4 on genetic disease research.

David Bumcrot serves as Scientific Fellow at CAMP4 Therapeutics. RNA therapeutics scientist and CAMP4 scientific fellow; previously served as the company’s chief scientific officer before its October 2025 leadership transition.

Karen Adelman serves as Scientific Advisor at CAMP4 Therapeutics. Gene regulation researcher advising CAMP4 on its regulatory RNA science.

Murray Stewart serves as Director at CAMP4 Therapeutics. Physician and biotechnology director who chairs CAMP4’s research and development committee.

Andy Schwab serves as Director at CAMP4 Therapeutics. 5AM Ventures investment leader whose biotechnology investing and board experience includes CAMP4 and multiple therapeutic and life science technology companies.

Michael MacLean serves as Director at CAMP4 Therapeutics. Biotechnology finance executive appointed to CAMP4’s board in March 2026.

Steve Holtzman serves as Director at CAMP4 Therapeutics. Biotechnology company director who previously chaired CAMP4; the company announced his transition to an independent director role in September 2025.

Alla Sigova serves as Senior Vice President, Platform at CAMP4 Therapeutics. Founding scientist who helped build CAMP4’s gene control mapping technology in 2016. Leads experimental and computational platform teams and previously worked on RNA therapeutics at Laronde.

Satya Kuchimanchi serves as Senior Vice President, Technical Operations at CAMP4 Therapeutics. Drug development and manufacturing specialist overseeing technical operations; trained in organic chemistry at Osmania University.

Caleb Moore serves as Chief Business Operations Officer at CAMP4 Therapeutics. Leads program strategy, portfolio decisions, alliance management and business operations; previously worked in corporate development at Acceleron Pharma.

Michelle Gates serves as Chief People Officer at CAMP4 Therapeutics. Human resources leader who previously spent sixteen years at Akamai Technologies, supporting international expansion, acquisitions and organizational development.

Daniel Tardiff serves as Chief Scientific Officer at CAMP4 Therapeutics. Previously led rare neurological disease research at Pfizer and helped found Yumanity Therapeutics, where his work included Parkinson’s disease drug discovery.

Yuri Maricich serves as Chief Medical Officer at CAMP4 Therapeutics. Physician and drug development executive overseeing CAMP4’s clinical development strategy. PKG Health appointed physician-scientist Yuri Maricich Chief Medical and Scientific Officer in August2023 and assigned him leadership of its Clinical Advisory Board. Its biography describes therapeutic-development work at Xdynia, Cavion, Corixa and Pear Therapeutics and education at Harvard, Washington, Notre Dame and Virginia. PKG’s July2025 directory retains his medical/scientific title; subsequent tenure after Empatica’s acquisition is unconfirmed and his separately established CAMP4 role is preserved.

Kelly Gold serves as Chief Financial Officer at CAMP4 Therapeutics. Biotechnology finance executive responsible for CAMP4’s financial strategy and operations.

Chief Financial Officer, Chief Operating Officer and Chief Compliance Officer of Trails Edge Capital Partners. The firm's SEC adviser filing identifies him as Matthew James Diaz; he signs biotechnology investment purchase agreements on behalf of the Trails Edge Biotechnology Master Fund.

Chief Investment Officer and principal of Trails Edge Capital Partners, the investment manager of the Trails Edge Biotechnology Master Fund. SEC filings identify him as Ortav Daniel Yehudai and document his authority over the manager's biotechnology investments.

Vice president of investor relations and communications at Immunic. Named as the company’s current investor contact on its official investor relations site and in company presentations.

Independent director of Immunic and former interim board chair. Previously led neuroscience and rare disease business strategy at Roche, with experience commercializing Ocrevus and other specialty medicines.

Independent director of Immunic and neurologist with expertise in multiple sclerosis. Previously led research and clinical programs at the Cleveland Clinic and worked at Biogen; trained at Case Western Reserve and Rochester.

Independent director of Immunic and biopharmaceutical finance executive. Has held leadership roles at Sionna, ACADIA, Alexion and Maverick Capital; trained at the University of Pennsylvania and is a CFA charterholder.

Independent director of Immunic, also known as Buck Phillips. Life sciences finance and operations executive with experience at Ribometrix, G1 Therapeutics, Novavax and Micromet and earlier venture investing experience.

Independent director of Immunic and life sciences investor and adviser. Former Curexsys chief executive and former partner at Life Sciences Partners, with earlier investment experience at DVC and Atlas Venture.

Director of Immunic and a BVF Partners investment professional. Previously worked at Monashee, Stifel and ClearView Healthcare Partners; trained in chemical engineering at Vanderbilt and holds a Notre Dame master's degree.

Chair of Immunic's board. Former Cubist Pharmaceuticals chief executive and Biogen commercial leader with experience launching multiple sclerosis medicines and guiding biotechnology companies. Mike Bonney is published by Kineticos Life Sciences as Strategic Advisor. Mike Bonney is a business executive with over 30 years of biotech and pharmaceutical expertise. Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating, and strategic roles, ending his career there as National Business Director. Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year. He was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011) and was named Top Performing MA CEO by Boston Business Journal in 2008. Bonney is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics, Gulf of Maine Research Institute, and Autolus Therapeutics. Bonney has served as a director with many companies previously including Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals. Bonney spends much of his time identifying and mentoring the next generation of life science leaders. He received his undergraduate degree in economics from Bates College. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Chief business officer of Immunic. Previously worked in business development at Akebia and corporate development at AVEO, with earlier consulting and healthcare investment banking experience.

General counsel of Immunic. Previously held legal leadership roles at Sandoz, Merck, Biogen and Pfizer, with experience in development, regulatory matters and commercial operations.

Chief data and digital officer of Immunic, appointed in September 2026. Leads enterprise data, analytics, AI and digital strategy; previously held data leadership roles at Avidity Biosciences, Edwards Lifesciences and Medtronic.

Chief development officer of Immunic. Has led global clinical development and operations across neurological, oncology and rare disease programs; holds a master's degree in biopharmaceutical sciences from Leiden.

Chief medical officer of Immunic, appointed in April 2026. Neurologist with drug development experience at Neurvati, GRIN Therapeutics, Wave Life Sciences, Sanofi Genzyme and Biogen.

Co-founder and chief scientific officer of Immunic, responsible for scientific strategy, preclinical studies and biomarkers. Previously worked at 4SC on development programs and holds a biology doctorate from Ludwig Maximilians University of Munich.

Chief financial officer of Immunic. Joined as principal accounting officer and controller in 2019 and became CFO in 2022; previously held finance leadership roles at Pernix, Alvogen and ImClone.

President and chief operating officer of Immunic. Previously led operations at Ovid Therapeutics and held multiple sclerosis commercial leadership roles at Novartis and Biogen.

Chief executive and director of Immunic, with experience commercializing multiple sclerosis medicines. Previously held commercial leadership roles at Genentech, including work on the Ocrevus launch and the tominersen development program.

Jeffrey Lu is an Aberdeen investment director in the Asia Pacific multi-asset and investment solutions team, overseeing quantitative portfolio and risk modelling. He joined the firm in 2017 after working at HKEX.

Loretta Tse is an investment director for the abrdn healthcare funds in the2026 own biography. She joined abrdn in2023 from Tekla, where she had been vice president since2015. Earlier experience includes biotechnology consulting, venture funds and start-ups, and a managing director role at Fred Hutchinson Cancer Research Center. She holds a UC Davis biochemistry BS and Johns Hopkins pharmacology/molecular sciences PhD.